Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension
<p><strong>Introduction</strong></p> Despite the increasing evidence supporting the efficacy of ambrisentan and bosentan in improving functional classes among pediatric patients with pulmonary arterial hypertension (PAH), there is a lack of information regarding their cost im...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Taylor and Francis
2023
|